Get access

Newer anticonvulsants: Lamotrigine

Authors


  • The authors have received funding from GlaxoSmithKline to partially fund their research on the risk of birth defects associated with use of lamotrigine. The authors are free to publish their own interpretation of the data, and GlaxoSmithKline had no part in the drafting of this letter.

No abstract is available for this article.

Get access to the full text of this article

Ancillary